A Study of WX390 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of WX390 in patients
with advanced solid tumors. The main questions it aims to answer are:
- PFS, OS, DoR at week 48;
- antitumor effects at week 24 and week 48. Participants will be treated with WX390
orally, and follow the efficacy and safety evaluation according to the protocol.